PriceTargets.com logo

Xenetic Biosciences - XBIO Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.04 As of 12/26/2024 06:23 PM ET
▼ -0.11 (-2.65%)

This chart shows the closing price for XBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Xenetic Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XBIO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Xenetic Biosciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.04.

This chart shows the closing price for XBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in Xenetic Biosciences. This rating has held steady since May 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/5/2024HC WainwrightReiterated RatingNeutral ➝ Neutral
11/22/2024HC WainwrightReiterated RatingNeutral
8/20/2024HC WainwrightReiterated RatingNeutral
5/16/2023HC WainwrightDowngradeBuy ➝ Neutral
4/11/2023HC WainwrightReiterated RatingBuy$40.00
5/2/2022HC WainwrightLower Target$50.00 ➝ $40.00
4/28/2022HC WainwrightReiterated RatingBuy
1/11/2021HC WainwrightBoost TargetBuy$20.00 ➝ $50.00
8/14/2020Maxim GroupInitiated CoverageBuy$25.00
8/13/2020HC WainwrightReiterated RatingBuy$20.00
6/17/2020HC WainwrightReiterated RatingBuy$20.00
5/4/2020HC WainwrightInitiated CoverageBuy
1/8/2020Maxim GroupInitiated CoverageBuy$25.00
(Data available from 12/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Xenetic Biosciences logo
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Read More

Today's Range

Now: $4.04
Low: $3.99
High: $4.28

50 Day Range

MA: $4.02
Low: $3.60
High: $4.53

52 Week Range

Now: $4.04
Low: $2.78
High: $5.20

Volume

20,875 shs

Average Volume

12,457 shs

Market Capitalization

$6.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Xenetic Biosciences?

The following Wall Street analysts have issued reports on Xenetic Biosciences in the last year: HC Wainwright.
View the latest analyst ratings for XBIO.

What is the current price target for Xenetic Biosciences?

0 Wall Street analysts have set twelve-month price targets for Xenetic Biosciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Xenetic Biosciences in the next year.
View the latest price targets for XBIO.

What is the current consensus analyst rating for Xenetic Biosciences?

Xenetic Biosciences currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in XBIO, but not buy more shares or sell existing shares.
View the latest ratings for XBIO.

What other companies compete with Xenetic Biosciences?

Other companies that are similar to Xenetic Biosciences include Akari Therapeutics, Cara Therapeutics, Hookipa Pharma, AEON Biopharma and Chemomab Therapeutics. Learn More about companies similar to Xenetic Biosciences.

How do I contact Xenetic Biosciences' investor relations team?

Xenetic Biosciences' physical mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The company's listed phone number is 781-778-7720 and its investor relations email address is [email protected]. The official website for Xenetic Biosciences is www.xeneticbio.com. Learn More about contacing Xenetic Biosciences investor relations.